Study Details
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
(IRB#: IRB_00189859)
This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term "risk" refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT.
- All genders
- All Ages
- Volunteers with special conditions
- In Person
- Unpaid
Who can participate?
Gender: All genders
Age: All Ages
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Patients with newly diagnosed Stage I-IV Favorable Histology Wilms Tumor confirmed by central review and with a qualifying Initial Stratum Assignment on APEC14B1.
- Patients with any uncontrolled, intercurrent illness including but not limited to symptomatic congestive heart failure.
- Patients with Stage I FHWT with a known or suspected Wilms Tumor predisposition syndrome or condition (contralateral nephrogenic rests and/or unilateral multicentric tumors) are excluded from treatment on the mVLR (Nephrectomy Only) arm.
- Patients who have an upfront nephrectomy must have at least one lymph node sampled and confirmed as a lymph node by central pathology review to be eligible.
Exclusion Criteria
- Patient with a diagnosis of Stage V Bilateral Wilms Tumor.
- Patients with any uncontrolled, intercurrent illness including but not limited to symptomatic congestive heart failure.
- Patients with Stage I FHWT with a known or suspected Wilms Tumor predisposition syndrome or condition (contralateral nephrogenic rests and/or unilateral multicentric tumors) are excluded from treatment on the mVLR (Nephrectomy Only) arm.
Will I be paid for my time?
No
IRB#: IRB_00189859
PI: Matthew Dietz
Department: PEDIATRIC HEMATOLOGY/ONCOLOGY
Approval Date: 2025-06-23 15:33:00
Study Categories: Cancer Studies
Specialties: Pediatric Hematology & Oncology
I am Interested